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Abstract
Purpose Bisphosphonates (BPs) are antiresorptive drugs
typically used to inhibit bone resorption. The latest re-
ports show that BPs play an important role in not only
achieving better bone mineral density but also in im-
proving bone microarchitecture. The mechanism of ac-
tion of the BPs is complex and multifactorial. We tried
to determine whether there are any changes in the
microarchitectural bone structure during local use of
BP (Pamifos 60). The aim of this study was to see if
BP-enriched cement used in rat models had positive
effects on bone formation.
Methods Research was performed on 40 adult male Wistar
rats that were divided into four groups: two control groups and
two experimental groups. Rats in the experimental groups
were implanted with BP-enriched cement into the bone, while
the control group rats were implanted with clean bone cement
(without BP). Micro-computed tomography was applied for
the investigation of trabecular microarchitecture of the prox-
imal physis of the tibial bone in all animals three and
six weeks after surgery. In all microCT images variables
such as bone volume density (BV/TV), trabecular thick-
ness (TbTh), trabecular separation (TbSp) and trabecular
number (TbN) were used to describe trabecular bone
morphometry.
Results The major finding of this study is that using BP-
enriched cement results in distinct changes in bone
microarchitecture. We showed that local use of pamidronate
(Pamifos 60) in orthopaedic cement had a positive effect on
bone formation. It significantly changed three variables. We
noticed increasing bone volume fraction and trabecular
thickness together with decreasing trabecular separation.
Conclusion In this paper we demonstrate the efficacy of
using BP-enriched cement in vitro in the tibiae of rats. Our
most significant finding based on micro-CT picture analysis
allows us to start further work on more suitable applications
of BP-enriched cement in humans. We believe that future
successful experiments will facilitate potential use of BP-
enriched cement in clinical applications.
Introduction
Bisphosphonates (BPs) are antiresorptive drugs typically used
to inhibit bone resorption. The latest reports show that BPs play
an important role not only in achieving better bone mineral
density but also in improving bone microarchitecture [1, 2].
The mechanism of action of the BPs is complex and
multifactorial [3–5]. However BPs have an affinity for
bone mineral and they act specifically on bone. During
resorption of bone by osteoclasts, the ingestion of BPs
interferes with specific intracellular processes, which
impair osteoclast function and ultimately cause apopto-
sis or cell death. BPs also regulate osteoblastic
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functions such as proliferation and differentiation, pre-
vent osteoblast apoptosis, modulate osteoblastic produc-
tion of extracellular matrix proteins, and regulate
osteoblastic expression and secretion of various growth
factors and cytokines [6, 7]. Several recent studies, both
preclinical and clinical, have focused on the potential
application of the BPs to the problems of bone catabo-
lism encountered in orthopaedics [8]. BP therapy is
effective in reducing bone turnover by decreasing bone
resorption rather than bone formation. BPs are widely
used in the treatment of many skeletal disorders such as
osteoporosis, malignant hypercalcaemia, bone metastasis
or Paget’s disease [9–11]. Some studies have shown that
nanomolar concentration of BPs had a positive effect on
osteoblast and osteocytes [12, 13]. It is reasonable to
believe that all those factors increase the bone density
and may have a positive influence on bone implant
osteointegration [14, 15]. It has also been shown that
local use of BPs inhibits mineralisation of bone tissue
and new bone formation [16].
The microarchitectural structure of bone due to
osteoclast-mediated resorption is of great clinical
importance for many bone diseases. BP effects have
been proven therapeutic in prevention of bone collapse
and also in enhancement of implant fixation. Neverthe-
less, further large scale in vivo clinical trials are re-
quired to confirm all benefits concerning orthopaedic
treatment.
We tried to determine whether there are any changes
in the microarchitectural bone structure after local use
of BP (Pamifos 60). The aim of the study was to see if
BP-enriched cement used in rat models had a positive
effect on bone formation.
Materials and methods
Animals
Wistar rats CRL(WI)WU BR were obtained from
Mossakowski Medical Research Centre Polish Academy
of Sciences. The experimental procedures were reviewed
and approved by the Bioethical Committee of Animal
Experimentation of the Medical University of Lublin.
Fig. 1 Micro-CT picture of tibial bone in rat six weeks after surgery with implanted cement which displayed the thresholding procedure
before appropriate 3D reconstruction
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Reagents
Bisphosphonate–pamidronate (Pamifos 60) was purchased
from Vipharm (Warsaw, Poland). Bone cement was pur-
chased from CMW 1, DePuy International Ltd, England.
Research was performed on 40 adult male Wistar rats,
with mean weight 240 g. Rats were divided into four groups,
ten rats each, in two control groups and two experimental
groups. Rats in experimental groups were implanted with
BP-enriched cement into the bone. While in the control
groups, rats were implanted with clean bone cement (with-
out BP). Because experimental groups were operated upon
at different times, each group was associated with its own
dedicated control group.
Animal model
The animals were anaesthetised using thiopental with depth
of anaesthesia being assessed by pedal reflex. After each
animal was anaesthetised, it was placed in a supine position
and the skin over both tibia bones was shaved and
disinfected. A skin incision was made over the proximal
part of the tibia. After exposing the proximal tibias identical
doses of freshly mixed bone cement were pressurised into
the bone canals through a pre-drilled hole using syringes
with modified 2.1-mm needles. Twenty rats were given pure
cement (control groups), while the remaining 20 rats were
given cement mixed with BPs. The wound was closed using
Vicryl sutures and staples. Three weeks after surgery, rats
from the first control group and from the first experimental
group were anaesthetised using thiopental (30 mg/kg), and
proximal parts of tibial bones were taken for examination by
micro-computed tomography. We performed the same pro-
cedure six weeks after surgery for the remaining rats in the
second control and second experimental groups.
Micro-computed tomography
In micro-computed tomography the microCT SkyScan 1072
system was used. The SkyScan 1072 represented high-
resolution desktop X-ray microtomography (Micro-CT) sys-
tems for in vitro scanning. Tomographic techniques were
applied for the investigation of trabecular microarchitecture
of the proximal physis of the tibial bone in all animals three
and six weeks after surgery. Probes were located centrally
on the tripod in the middle of the microtomography cam-
era’s area of sight. Then probes were scanned (magnifica-
tion 34×; pixel 8.42; rotation step 0.23; exposure 1.9 s; gain
1). Raw scans were reconstructed with the nRecon program
(Skyscan, Belgium). Then the CTan program (Skyscan,
Belgium) was used for detailed analysis.
Bone samples were selected from identical levels, beneath
the lowest level of applied cement or BP-enriched cement
implanted into the bone chosen during micro-CT before 3D
reconstruction, as the threshold. The thresholding procedure
allowed us to distinguish clearly between the cement or BP-
enriched cement and the bone tissue (Fig. 1). The comparison
of morphometric parameters extracted from the different
images revealed specific changes in bone morphology.
Morphometric analyses were based on 3D algorithms of
identical ROI (regions of interest; Fig. 2) in all probes,
whereby a cylinder was positioned in the centre of the
proximal physis of the tibia bone. That cylinder was
visually located at an identical distance from the most
distal part of the implanted cement which was used as a
benchmark. We used standardised nomenclature and
Fig. 3 Micro-CT cross-section
picture of tibial bone in rat
six weeks after surgery in the
group of animals implanted
with BP-enriched cement (1)
compared to corresponding
micro-CT picture of rat
implanted with cement without
BP (2)
Fig. 2 Morphometric micro-CT analyses based on 3D algorithms of
identical ROI (regions of interest)
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symbols for bone histomorphometry [17]. In all microCT
images variables such as bone volume (BV), trabecular
thickness (Tb.Th), trabecular separation (Tb.Sp) and tra-
becular number (Tb.N) were analysed.
Statistical analysis
All data are presented as means ± SD. Differences and corre-
lations were considered significant when p<0.05. An
ANOVA (analysis of variance) table was used for variance
analysis to detect the existence of differences between the
groups of rats that were investigated. All statistical
calculations were performed using 6.0 STATISTICA software
(StatSoft, Poland).
Results
The major finding of this study is that using BP-enriched
cement results in distinct changes in bone microarchitecture
(Fig. 3). High resolution micro-CT in vitro bone analysis
showed an increase of bone volume (BV) in a group of rats
implanted with BP-enriched cement after three weeks of
treatment when compared to the control group. However
there were no statistically significant differences between
the groups studied (P=0,444; Fig. 4). Nevertheless after
Trabecular thickness (TB.Th) 3 weeks
Fig. 6 Increase of trabecular thickness (Tb.Th) in the group of rats
implanted with BP-enriched cement three weeks after surgery com-
pared to the group of rats implanted with pure cement
Trabecular thickness (Tb.Th) 6 weeks
Fig. 7 Increase of trabecular thickness (Tb.Th) in the group of rats
implanted with BP-enriched cement six weeks after surgery compared
to the group of rats implanted with pure cement
Bone volume (BV) 6 weeks
Fig. 5 Increase of bone volume (BV) in the group of rats implanted
with BP-enriched cement six weeks after surgery compared to group of
rats implanted with pure cement
Bone volume (BV) 3 weeks
Fig. 4 Bone volume (BV) in the group of rats implanted with BP-
enriched cement three weeks after surgery compared to group of rats
implanted with pure cement
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six weeks of treatment statistics showed a significant in-
crease of bone volume in rats implanted with BP-enriched
cement (BV, P=0.034; Fig. 5) compared to the group
implanted with pure cement.
We also noted a statistically significant increase of tra-
becular thickness (Tb.Th) in both groups (three and
six weeks) of rats implanted with BP-enriched cement com-
pared to rats implanted with pure cement (Tb.Th, P=0.003;
Tb.Th, P=0.014; Figs. 6 and 7). Though, three weeks after
surgery we did not notice a significant decrease of trabecular
separation in rats implanted with BP-enriched cement com-
pared to rats implanted with cement without BP (Tb.Sp, P=
0.835; Fig. 8). Nonetheless six weeks after surgery we
registered a significant decrease of that variable (Tb.Sp)
between the control group and the group implanted with
BP-enriched cement (P=0.015; Fig. 9).
In micro-CT analysis performed three and six weeks after
surgery in groups of rats implanted with BP-enriched ce-
ment we did not obtain a statistically significant increase of
trabecular numbers (P=0.706; P=0.231; Fig. 10).
Discussion
The future potential use of BPs in orthopaedics encourages
us to investigate the local use of this substance. Animal
Trabecular number (Tb.N) 6 weeks
Trabecular number 3 (Tb.N) weeks
Fig. 10 Trabecular numbers (Tb.N) in both groups implanted with
BP-enriched cement three and six weeks after surgery compared to
groups of rats implanted with pure cement
Trabecular separation (Tb.Sp) 6 
weeks
Fig. 9 Decrease of trabecular separation (Tb.Sp) in the group of rats
implanted with BP-enriched cement six weeks after surgery compared
to groups of rats implanted with pure cement
Trabecular separation (Tb.Sp) 3 weeks
Fig. 8 Trabecular separation (Tb.Sp) in the group of rats implanted
with BP-enriched cement six weeks after surgery compared to the
group of rats implanted with pure cement
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studies have shown that BPs inhibit bone resorption at the
bone–implant interface [18]. BPs can also inhibit osteolysis
by interacting directly with the osteoclasts. Experimental
results made by Agholme et al. showed that soaking bone
grafts in BP solution can prevent their resorption and in-
crease the local bone density in rats. They indicated that
local use of BPs might be a great factor against bone
resorption; improving the bone’s microarchitecture and en-
hancing implant fixation without affecting the whole organ-
ism [15]. Experimental in vitro and in vivo research has
shown great potential of using BPs in healing fractured
bones, reducing osteoarthritis or enhancing bone allografts
ingrowth [19–24].
Our micro-CT results showed only beneficial effects on
the bone’s microarchitecture, which is similar to the obser-
vations of others [25]. In the rat model presented we did not
notice any aggravation in the bone’s microarchitecture or
other negative effects reported by other authors [26, 27].
High-resolution micro-computed tomography (microCT)
imaging allowed us to assess bone morphology. Analyses
based on 3D algorithms showed specific changes in three
out of four variables that should be used to describe trabec-
ular bone morphometry. Pamidronate implanted in cement
did not affect the trabecular numbers, which is similar to
other reports [27, 28]. Despite that fact some authors noticed
significant changes in trabecular numbers during oral use of
BPs in the paediatric population. Although they did not
notice any changes in trabecular thickness, it was also noted
that it might have been difficult to interpret because of the
pathological process of specific diseases and the growth
process in the young population [29]. We proved that local
use of pamidronate (Pamifos 60) in orthopaedic cement
significantly increases two variables: bone volume and tra-
becular thickness. We also noticed a significant decrease of
trabecular separation. When reporting micro CT results Gao
et al. presented similar results. Although, their implants
before surgery had been rinsed in a solution containing
various BPs: pamidronate, zoledronic acid or ibandronate
[28]. Besides consistent changes in the parameters of tra-
becular microstructure they also reported effective induction
of a greater restoration in the bone volume, which is similar
to our findings.
Patients who need arthroplastic surgery are in high risk
for osteopenia or osteoporosis [30]. Several recent studies
have shown the utility of local application of various BPs on
titanium implants [31–35]. In our opinion local BP treat-
ment may be more beneficial considering some of the side
effects connected with oral BP treatment [36, 37]. Further-
more, our micro-CT analysis showed great potential in the
local use of BP-enriched cement. In the data presented,
implanted BP-enriched cement simply changes the bone
turnover in normal rats’ bone toward a positive balance
between bone formation and bone resorption. As mentioned
previously specific binding affinities and pharmacokinetics
of pamidronate have different effects on osteoclasts and
osteoblasts. However, its detailed mechanism of action is
not completely understood. Pamidronate (Pamifos) appears
to adsorb to calcium phosphate crystals in bone, blocking
their dissolution by inhibiting osteoclast-mediated bone re-
sorption. All those factors lead to positive effects on bone
formation together with enhanced growth.
In our earlier report we proved that use of the
bisphosphonate, Pamifos 60, that was present in the cement
had a positive effect on bone turnover. BP stimulated increase
in OPG and the RANKL decrease in the bone microenviron-
ment markers in rat serum were important components of the
mechanisms reducing bone resorption.
In this paper we also demonstrated the effectiveness of
the idea of using BP-enriched cement in vitro in tibiae of
rats. Our most significant findings based on micro-CT pic-
ture analysis allow us to start further work on more suitable
applications of BP-enriched cement in humans. We believe
that successful experiments will facilitate potential use of
BP-enriched cement in clinical application.
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